Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

Sponsor
Assiut University
Study ID
NCT03577743
Phase
PHASE2
Status
Completed

Conditions

  • Efficacy
  • Metastatic Triple Negative Breast Cancer
  • Safety Issues

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Bevacizumab — DRUG
    -bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .

Study Details

Evaluating efficacy and safety of bevacizumab when combined with chemotherapy (carboplatin and Paclitaxel ) in treatment of patient with metastatic triple negative breast cancer

Key Dates

First listed
Jul 5, 2018
Start date
Jul 1, 2018
Status verified
Mar 2021
Primary completion
Mar 15, 2020
Completion
Feb 15, 2021

Study Design

Enrollment
54 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: experimental arm
    bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity

Primary Outcome Measure

- progression free survival [ Time Frame: after six month from last enrollment ]

Related Studies